Recent Articles in Featured Companies

Sinoasis Pharmaceuticals, a young Guangzhou biopharma founded in 2003, is building its business around a proprietary platform technology for discovering fully human therapeutic antibodies. “We have a technology that can functionally select an antibody or domains with thermodynamic stability,” said Shengfeng Li, PhD, in an exclusive ChinaBio® Today interview. Thermodynamic stability “is one of the key properties for therapeutic antibodies as they often require a long half-life,” he explained. More details...

HD Biosciences Co., Ltd., the Shanghai-based biotech CRO, was given the “2008 Top Research Service Partner” award by multinational big pharma Pfizer. The award was given to recognize the quality, productivity, and value that HD Biosciences delivered in its collaboration with Pfizer during the past year. We profile the company and include an exclusive interview with CEO and Founder Dr. Xuehai Tan.  More details...

Stock Symbol: (NYSE: PFE)

Drug resistant strains of pathogens are an urgent unmet need, but currently, despite the large market opportunity, there are no new classes of antibiotics in clinical development. ProteLight Pharmaceuticals （长春普莱医药生物技术有限公司）of China and BioAMPs International of Denver, CO want to change that. Together, the two companies own the worldwide rights to V13K, a peptide-based antibiotic currently in pre-clinical development. As a peptide, V13K attacks the membrane of the pathogen, instead of targeting a metabolic pathway as a small-molecule drug would do. In an exclusive interview with ChinaBio® Today, the CEOs discuss their companies....